Clinical Trial Success: Recent discussions on X about Natera, Inc. (NTRA) have been ignited by the company's announcement of a 41% improvement in overall survival for bladder cancer patients in the IMvigor011 trial. Many users are highlighting this as a potential game-changer for the company’s Signatera product in molecular recurrence detection. The buzz reflects optimism about Natera’s role in advancing cancer diagnostics.
Insider Sales and Market Sentiment: Alongside the trial news, posts on X have also noted recent insider sales by Natera’s CFO, raising questions about confidence in the stock’s near-term trajectory. Some discussions point to the stock’s high market cap and debate whether current prices reflect future growth potential. This mix of clinical excitement and insider activity keeps the conversation dynamic.
Analyst Upgrades: Adding fuel to the dialogue, recent analyst upgrades, including a raised price target by BTIG Research, have been mentioned frequently on X. Users seem intrigued by the positive outlook on Natera’s long-term growth in genetic testing. The chatter remains active as investors weigh clinical wins against market positioning.
Note: This discussion summary was generated from an AI condensation of post data.
Natera, Inc. Congressional Stock Trading
Members of Congress have traded $NTRA stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 3 times. They made 2 purchases worth up to $30,000 on 09/22, 08/22 and 1 sale worth up to $15,000 on 07/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Natera, Inc. Insider Trading Activity
Natera, Inc. insiders have traded $NTRA stock on the open market 182 times in the past 6 months. Of those trades, 0 have been purchases and 182 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 15 sales selling 122,436 shares for an estimated $20,655,165.
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 25 sales selling 68,032 shares for an estimated $10,567,278.
- JONATHAN SHEENA has made 0 purchases and 66 sales selling 44,024 shares for an estimated $7,358,215.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 8 sales selling 26,187 shares for an estimated $4,349,333.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 28 sales selling 25,519 shares for an estimated $3,934,581.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 19 sales selling 18,162 shares for an estimated $2,794,549.
- GAIL BOXER MARCUS has made 0 purchases and 13 sales selling 14,795 shares for an estimated $2,316,079.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 7 sales selling 6,213 shares for an estimated $941,038.
- ROWAN E CHAPMAN sold 2,750 shares for an estimated $459,222
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Natera, Inc. Hedge Fund Activity
We have seen 365 institutional investors add shares of Natera, Inc. stock to their portfolio, and 272 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 3,263,822 shares (+44.3%) to their portfolio in Q2 2025, for an estimated $551,390,088
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,650,073 shares (+15.7%) to their portfolio in Q2 2025, for an estimated $278,763,332
- CITADEL ADVISORS LLC removed 1,301,513 shares (-61.3%) from their portfolio in Q2 2025, for an estimated $219,877,606
- KYNAM CAPITAL MANAGEMENT, LP removed 1,167,570 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $197,249,275
- CAPITAL WORLD INVESTORS added 1,013,229 shares (+255.6%) to their portfolio in Q2 2025, for an estimated $171,174,907
- LORD, ABBETT & CO. LLC removed 736,644 shares (-48.4%) from their portfolio in Q2 2025, for an estimated $124,448,637
- POINTSTATE CAPITAL LP removed 615,287 shares (-81.4%) from their portfolio in Q2 2025, for an estimated $103,946,585
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Natera, Inc. Government Contracts
We have seen $296,845 of award payments to $NTRA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- MODIFICATION TO EXTEND THE POP FOR SIX (6) MONTHS: $140,595
- GENETIC TESTING: $79,200
- TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $77,050
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Natera, Inc. Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 10/23/2025
- Canaccord Genuity issued a "Buy" rating on 10/14/2025
- Stephens & Co. issued a "Overweight" rating on 08/15/2025
- Piper Sandler issued a "Overweight" rating on 08/11/2025
- RBC Capital issued a "Outperform" rating on 08/08/2025
- Barclays issued a "Overweight" rating on 08/08/2025
- Evercore ISI Group issued a "Outperform" rating on 07/28/2025
To track analyst ratings and price targets for Natera, Inc., check out Quiver Quantitative's $NTRA forecast page.
Natera, Inc. Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 9 analysts offer price targets for $NTRA in the last 6 months, with a median target of $210.0.
Here are some recent targets:
- Mark Massaro from BTIG set a target price of $210.0 on 10/23/2025
- Kyle Mikson from Canaccord Genuity set a target price of $200.0 on 10/14/2025
- Brandon Couillard from Wells Fargo set a target price of $175.0 on 09/22/2025
- Mason Carrico from Stephens & Co. set a target price of $183.0 on 08/15/2025
- David Westenberg from Piper Sandler set a target price of $220.0 on 08/11/2025
- Conor McNamara from RBC Capital set a target price of $255.0 on 08/08/2025
- Luke Sergott from Barclays set a target price of $210.0 on 08/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
